Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 9 - Medicinal preparations characterised by special physical form
Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044)
03/2003
03/13/2003WO2003020763A2 Soluble t cell receptor
03/13/2003WO2003020753A1 Peptidic compounds selectively binding to p-selectin
03/13/2003WO2003020751A2 Homing peptides
03/13/2003WO2003020747A1 Modified peptides and their use for the treatment of autoimmune diseases
03/13/2003WO2003020736A1 Crystaline clindamycin free base
03/13/2003WO2003020638A1 Compositions comprising rigid-rod polymers and carbon nanotubes and process for making the same
03/13/2003WO2003020336A2 Stabilizing catheter for protein drug delivery
03/13/2003WO2003020335A2 Dual stage microvalve and method of use
03/13/2003WO2003020324A2 Methods for sterilizing preparations of digestive enzymes
03/13/2003WO2003020320A2 Nanoparticles comprising biologically active tnf which is immobilised on the same
03/13/2003WO2003020319A1 A w/o-emulsion carrier composition
03/13/2003WO2003020318A1 A topical w/o-emulsion composition
03/13/2003WO2003020316A1 Materials sustainedly releasing drug in vivo
03/13/2003WO2003020293A1 Health-care product for regulating blood glucose and its preparation method
03/13/2003WO2003020291A1 Increased solubility flavanolignan preparations
03/13/2003WO2003020265A2 Compositions comprising pectin and ascorbic acid
03/13/2003WO2003020261A1 Pharmaceutical composition comprising lumiracoxib
03/13/2003WO2003020253A2 Pharmaceutical compositions for the treatment of asthma
03/13/2003WO2003020250A1 Plaster for the treatment of dysfunctions and disorders of nail growth
03/13/2003WO2003020249A1 Plaster for the treatment of dysfunctions and disorders of nails
03/13/2003WO2003020248A1 Plaster for the treatment of dysfunctions and disorders of nails, comprising sertaconazole
03/13/2003WO2003020247A1 Process for coating solid particles
03/13/2003WO2003020246A1 Injection molding process for the preparation of an oral delivery device for a pharmaceutically active agent
03/13/2003WO2003020245A1 Residual solvent extraction method and microparticles produced thereby
03/13/2003WO2003020244A1 Process for dispersing a fluid in solid particles
03/13/2003WO2003020243A1 Combination dosage form containing a cholesterol -lowering agent , an inhibitor of the renin-angiotensin, and aspirin
03/13/2003WO2003020242A1 Sustained release preparations
03/13/2003WO2003020241A2 Functional powders for oral delivery
03/13/2003WO2003020240A2 Therapeutic agent delivery tampon
03/13/2003WO2003020235A2 Stabilisation of oxidation-sensitive and uv-sensitive active ingredients
03/13/2003WO2003020219A2 Aerosolized decongestants for the treatment of sinusitis
03/13/2003WO2003020211A2 Nitric oxide generation
03/13/2003WO2003020210A2 Vaginal delivery of chemotherapeutic agents and inhibitors of membrane efflux systems for cancer therapy
03/13/2003WO2003020203A2 Hydrogenated castor oil dispersed in a lipid for pharmaceutically elegant topical ointments
03/13/2003WO2003020172A1 An implantable and sealable system for unidirectional delivery of therapeutic agents to targeted tissues
03/13/2003WO2003020161A2 Immune modulation device for use in animals
03/13/2003WO2003020037A1 Multivesicular emulsion topical delivery systems
03/13/2003WO2003020031A1 Use of non-toxic crosslinking reagents to improve fatigue resistance and reduce mechanical degradation of intervertebral disc and other collagenous tissues
03/13/2003WO2003000225A3 Pharmaceutical formulation having a masked taste and method for the production thereof
03/13/2003WO2003000174A3 Compositions and methods for intracellular delivery
03/13/2003WO2002096447A3 Pharmaceutical preparation containing active ingredients extracted from the plants centella asiatica, mahonia aquifolium and viola tricolor
03/13/2003WO2002094774A3 Oxcarbazepine dosage forms
03/13/2003WO2002089796A3 Methods for selective immunomodulation using pimecrolimus
03/13/2003WO2002088666A3 Method for identifying lymph nodes
03/13/2003WO2002083840A3 Compositions and methods for transepithelial transport of membrane-bounded vesicles and virions
03/13/2003WO2002083097A3 Drug delivery system for hydrophobic drugs
03/13/2003WO2002074343A3 The use of non-digestible polymeric foams to sequester ingested materials, thereby inhibiting their absorption by the body
03/13/2003WO2002074158A3 Two-phase processing of thermosensitive polymers for use as biomaterials
03/13/2003WO2002072033A3 Chronotherapeutic dosage forms containing glucocorticosteroid
03/13/2003WO2002069939A3 Taste masked pharmaceutical compositions
03/13/2003WO2002068015A3 Modular infusion device and method
03/13/2003WO2002067902A3 Modulation of release from dry powder formulations
03/13/2003WO2002067846A3 A vaccine composition and method of using the same
03/13/2003WO2002062832A3 Modified human brain-derived neutrophic factor (bdnf) with reduced immunogenicity
03/13/2003WO2002060379A3 Composition comprising extracts of flos lonicerae, fructus forsythiae and radix scutellariae, uses and preparation thereof
03/13/2003WO2002058667A3 Improved process for the production of sustained release drug delivery devices
03/13/2003WO2002055062A3 Pharmaceutical tablet comprising paroxetine mesylate
03/13/2003WO2002051379A3 Thixotropic nasal spray
03/13/2003WO2002047662A3 Antibiotic/benzoyl peroxide dispenser
03/13/2003WO2002045703A3 Mixtures or organic compounds for the treatmentof airway diseases
03/13/2003WO2002045684A3 Rapidly dispersing pharmaceutical composition comprising effervescent agents
03/13/2003WO2002041878A3 Titratable dosage transdermal delivery system
03/13/2003WO2002040083A3 Transcutaneous delivery means
03/13/2003WO2002034293A3 Use of citric acid as antimicrobial agent or enhancer or as anticancer agent
03/13/2003WO2002030398A3 Delayed release pharmaceutical formulations
03/13/2003WO2002030391A3 Method for determining the release of a peptide from a sustained release polylactide formulation
03/13/2003WO2002020056A3 Methods and compositions for producing a neurosalutary effect in a subject
03/13/2003WO2002003957A3 Compositions for sustained release of antineoplastic taxanes, and methods of making and using the same
03/13/2003WO2001036515A3 Polymeric compositions and a method of making the same
03/13/2003US20030050626 Infusion device and inlet structure for same
03/13/2003US20030050625 Infusion device and driving mechanism for same
03/13/2003US20030050624 Infusion device and driving mechanism for same
03/13/2003US20030050623 Implantable infusion device and reservoir for same
03/13/2003US20030050622 Device and method to maintain vascularization near implant
03/13/2003US20030050621 Safety limits for closed-loop infusion pump control
03/13/2003US20030050620 Combinatorial type controlled release drug delivery device
03/13/2003US20030050595 Pellet implant system and method of administration
03/13/2003US20030050591 Loading system and method for using the same
03/13/2003US20030050535 Ambulatory medical apparatus and method using a telemetry system with predefined reception listening periods
03/13/2003US20030050344 Thyroid hormones or their salts in capsule or in swallowable uniform soft-gel gelatin matrices for treatment of hypothyroidism
03/13/2003US20030050343 Novel potentiating compounds
03/13/2003US20030050318 Stable water in oil aminophylline emulsions
03/13/2003US20030050312 Novel tablets and capsules and a process for its preparation
03/13/2003US20030050303 Treating neutrophils and eosinophils in the tissue of the eye or nasal mucous membrane
03/13/2003US20030050292 Applying a hydroalcoholic gel that comprises testosterone to the skin of a male
03/13/2003US20030050290 Combination of formoterol and mometasone furoate for asthma
03/13/2003US20030050283 Composition for the treatment and/or prevention of macular degeneration, method for its manufacture, and its use for treating the eye
03/13/2003US20030050278 Agent and food for inhibiting IgE antibody
03/13/2003US20030050265 A compound 8 to 50 nucleobases in length targeted to a nucleic acid molecule encoding transforming growth factor-beta 2
03/13/2003US20030050262 Inhibition of neurodegeneration
03/13/2003US20030050261 Immunostimulatory nucleic acid molecules
03/13/2003US20030050255 An ophthalmic formulation containing an ascomycin and at least one polymer selected from ethylene oxide-propylene oxide copolymer and a crosslinked acrylic acid polymer
03/13/2003US20030050252 An active ingredient from the group of an antihistamine, a decongestant, an antitussive or anticholinergic is dissolved in a solvent and added to a dispersion of tannic acid in the water to form the tannate salt complex
03/13/2003US20030050238 Stable composition comprising epidermal growth factor as an active ingredient
03/13/2003US20030050225 Compositions and methods to control bleeding
03/13/2003US20030049865 Microfabricated devices for the storage and selective exposure of chemicals and devices
03/13/2003US20030049447 Reaction product of pigment, water and lipophilic compound; cosmetics, food, drugs, agriculture
03/13/2003US20030049440 Containing acrylate ester copolymer, organometallic compound and polyol
03/13/2003US20030049340 Use of a preparation of cimicifuga racemosa
03/13/2003US20030049325 Compressed nontoxic carrier; sponge expansion in stomach; sustained release
1 ... 2167 2168 2169 2170 2171 2172 2173 2174 2175 2176 2177 2178 2179 2180 2181 2182 2183 2184 2185 2186 2187 ... 2991